

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



REAL NUTRICEUTICAL GROUP LIMITED

瑞年國際有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 2010)

SUSPENSION OF TRADING: RESUMPTION GUIDANCE

This announcement is made by Real Nutraceutical Group Limited (“**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 22 August 2018, 24 August 2018, 31 August 2018, 19 December 2018 and 10 January 2019 (collectively, the “**Announcements**”) respectively in relation to, among other things, (a) that Wuxi Ruinian Industry & Commerce Co., Limited, a subsidiary of the Company, was under investigation by the Wuxi Public Securities Bureau (無錫市公安局) and Mr. Wang Fucai, the chairman of the board (“**Board**”) of directors of the Company (“**Directors**”), the chief executive officer of the Company and an executive Director, has been imposed by the police in the PRC criminal coercive measures (刑事強制措施) (“**Reported Incidents**”); (b) the suspension (“**Suspension**”) of trading in the shares of the Company on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) with effect from 9:00 a.m. on 4 July 2018 as directed by the Securities and Futures Commission (“**SFC**”) pursuant to its power under Rule 8(1) of the Securities and Futures (Stock Market Listing) Rules (“**Rule 8(1)**”); (c) the issues and concerns raised by the SFC leading to its exercise of its power under Rule 8(1) as aforesaid; (d) the transitional arrangements under the amended delisting framework applied to the Company under the amended Listing Rules effective from 1 August 2018; (e) the delay in publication of the interim results for the six-month period ended 30 June 2018; (f) poll results of the Extraordinary General Meeting held on 18 December 2018; and (g) the removal and appointment of Executive Directors, and the appointment of Independent Non Executive Directors.

RESUMPTION GUIDANCE

On 10 September 2018, the Company has been notified by the Stock Exchange of the following resumption guidance (“**Resumption Guidance**”) for the Company:

- (i) publish outstanding financial results and address any audit qualifications; and
- (ii) inform the market of all material information for the shareholders and the investors to appraise the Company’s position.

In addition, the Stock Exchange required the Company to remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange’s satisfaction before the trading in its securities is allowed to resume and the Company was reminded of its primary responsibility to devise its action plan for resumption.

The Stock Exchange has indicated that it might modify or supplement the Resumption Guidance if the Company’s situation changes.

UPDATE ON THE SUSPENSION OF TRADING

The Company appointed new Executive Directors and Independent Non-Executive Director on 3 January 2019. The new Board has authorized the appointment of Executive Directors Mr. Kwan Sai Bun, Daniels and Ms. Vivian Yan to be the executive directors and/or legal representative of the Company’s major subsidiaries in British Virgins Islands, Hong Kong and the PRC.

The Board removed Dr. Wang Fucui, Mr. Zhang Yan, Mr. Yi Lin, Mr. Li Lin and Mr. Yu Yan as Executive Directors pursuant to the poll results of Extraordinary General Meeting held on 18 December 2018.

Board members met representatives of the Company’s auditor in the first week of January 2019 and were assured of all necessary cooperation by the auditor in the resumption of trading of the Company’s shares. A Board member also visited major product facilities in Wuxi in the second week of January 2019 to assess latest business operation status.

The Board will investigate the Company’s latest assets positions as soon as possible and report to the shareholders at appropriate time.

UPDATE ON BUSINESS OPERATIONS

The production of the Company’s health supplements products in Wuxi continues and the business operation carries on, both at a reduced scale.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange will remain suspended until further notice. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

On behalf of the Board
Real Nutraceutical Group Limited

Mr. Leung Wai Man, Raymond	Mr. Kwan Sai Bun, Daniels	Dr. Chow Pok Yu, Augustine	Ms. Yan, Vivian
---------------------------------------	--------------------------------------	---------------------------------------	------------------------

Executive Directors

Hong Kong, 24 January 2019

As at the date of this announcement, the Executive Directors are Mr. Leung Wai Man, Raymond, Mr. Kwan Sai Bun, Daniels, Dr. Chow Pok Yu, Augustine, and Ms. Yan, Vivian, and the Independent Non-Executive Directors of the Company are Mr. Ngai Wah Sang, Mr. Wong Kwok On and Mr. Yuen Ching Bor Stephen.